SPEAKERS

Dr. Ie-Ming Shih is the Richard W. TeLinde Distinguished Professor of Gynecologic Pathology in the Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine. He is also the director of the TeLinde inter-departmental gynecologic disease research program and a co-director of the Women’s Malignancy Group at the Sidney Kimmel Comprehensive Cancer Center. Originally from Taiwan, he moved to the U.S. to pursue a PhD degree at the University of Pennsylvania. He completed his training at the Johns Hopkins Hospital. After finishing a residency, clinical fellowship, and research fellowship at Hopkins, he became a faculty member there in 2000. 

Dr. Shih has served as an attending pathologist at the Johns Hopkins Hospital, with clinical expertise in ovarian cancer, uterine cancer, endometriosis, and gestational trophoblastic diseases. His research focuses on understanding the diagnostic, molecular, and pathogenic aspects of various gynecologic cancers. The research findings from his team have contributed to establishing the tubal paradigm in the genesis of ovarian serous carcinoma and have led to a new hypothesis in the pathogenesis of endometriosis. Additionally, he is a dedicated educator, mentoring students, fellows, junior faculty, and pathologists worldwide. He has served on various advisory boards, and currently, Dr. Shih is a senior editor of AACR Cancer Research and an editorial member of the recent World Health Organization (WHO) Classification of Female Genital Tumors.       

Over the past two decades, his research has received continuous support from the NIH/NCI, the US Department of Defense Ovarian Cancer Research Program, and several private foundations. As supported by these research grants, he has dedicated himself to advancing next-generation pathology research and innovation by integrating spatial technologies, single-cell analysis, micro-omics, and computational/AI tools. 

Dr. Shih has published over 400 peer-reviewed research articles in NEJM, Cancer Cell, PNAS, Science, Lancet Oncology, Nature, and Nature Medicine, with an H-index of 130. He received the Rosalind Franklin Prize for Excellence in Ovarian Cancer and the NIH Specialized Program of Research Excellence award. 

CURRENT POSITION

Section Chief, Department of Obstetrics and Gynecology

National Hospital Organization Tokyo Medical Center

Address:　2-5-1 Higashigaoka, Meguro-ku, Tokyo, Japan

Tel: +81-3-3411-0111

Fax: +81-3-3412-9811

E-mail: yama2397@gmail.com

EDUCATION

April 1987 – March 1993

Keio University School of Medicine, Tokyo, Japan

Medical License obtained

May 1999 – September 2005

Keio University School of Medicine, Tokyo, Japan

Doctor of Medical Science (Ph.D.)

PROFESSIONAL EXPERIENCE

May 1993 – April 1995

Resident, Keio University Hospital

May 1995 – June 1999

Assistant, Keio University School of Medicine

July 1999 – June 2002

Staff Physician, Department of Obstetrics and Gynecology

National Tochigi Hospital

July 2002 – March 2015

Staff Physician, National Hospital Organization Tokyo Medical Center

April 2015 – Present

Chief, Department of Obstetrics and Gynecology

National Hospital Organization Tokyo Medical Center

BOARD CERTIFICATIONS (Official Society Titles)

1998 Board Certified Specialist, Japan Society of Obstetrics and Gynecology (JSOG)

1999 Board Certified Specialist, Japan Society of Clinical Cytology (JSCC)

2008 Board Certified Specialist, Japan Society of Gynecologic Oncology (JSGO)

2019 Board Certified Specialist in Endoscopic Surgery, Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy (JSGOE)

ACADEMIC AND PROFESSIONAL POSITIONS

2023 – Present

Board Member, Japan Society of Clinical Cytology

2022 – Present

Board Member, Japanese Society of Gynecologic Pathology

May 2020 – April 2022

President, Tokyo Metropolitan Society of Clinical Cytology

2015 – Present

Council member, Japan Society of Gynecologic Oncology

AREAS OF SPECIALIZATION

Ablative therapy for cervical intraepithelial lesions

Minimally invasive surgery, particularly robotic surgery (da Vinci SP)

Sentinel lymph node navigation surgery

CLINICAL TRIALS (Selected)

Principal Investigator (PI), Matisse Trial

(Maternal Immunization Study for Safety and Efficacy)

Hyun-Soo Kim, MD, PhD, is a gynecologic pathologist and Associate Professor of Pathology and Translational Genomics at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. He graduated from Kyung Hee University School of Medicine in 2006 and earned his PhD from the same institution in 2015. Following his doctoral training, Dr. Kim joined Severance Hospital in 2016 as a faculty member, specializing in gynecologic pathology. In 2019, he moved to Samsung Medical Center, where he continues his clinical and academic work in gynecologic pathology. From 2024 to 2025, Dr. Kim served as an international visiting pathologist and fellow under Dr. Esther Oliva at Massachusetts General Hospital, Boston, MA, gaining advanced experience in gynecologic pathology and international collaborative research. Dr. Kim is an active member of the United States and Canadian Academy of Pathology (USCAP), the International Society of Gynecological Pathologists (ISGyP), the Korean Society of Pathologists (KSP), the Korean Society for Cytopathology (KSC), the Korean Society of Gynecologic Oncology (KSGO), and the Korean Gynecologic Oncology Group (KGOG). He currently serves as the Secretary of the Gynecologic Pathology Study Group of the KSP. His primary research interest lies in rare gynecologic tumors, with a particular focus on mesonephric-like adenocarcinoma (MLA), and he is participating in the MLA Consortium led by MD Anderson Cancer Center, Houston, TX, engaging in international collaborative research and attending annual consortium meetings.

My academic interests focus on gynecologic pathology, bone and soft tissue pathology, with a strong passion for molecular pathology. Over the years, I have gained valuable experience in molecular pathology diagnosis and next-generation sequencing (NGS) analysis. I’ve also had the opportunity to contribute to the professional association, including serving as Secretary-General of the Taiwan Pathology Society from 2021 to 2023. Since 2023, I have been honored to continue as a councilor for the society.

In addition to my clinical and educational roles, I've had the opportunity to contribute to laboratory development (LDT) in Taiwan. I've served as an Advisory Member for the Taiwan Ministry of Health and Welfare (MOHW), a Reviewer for the Joint Commission of Taiwan (JCT), and an Inspector for Precision Medicine Molecular Testing Laboratory Certification under the Taiwan Food and Drug Administration (TFDA).